RedHill Biopharma Faces Nasdaq Notification
RedHill Biopharma Ltd. (Nasdaq: RDHL), a noted biopharmaceutical firm, has recently received an important notification from the Nasdaq Stock Market. The written notification indicates that the company is currently not in compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000 for continued listing on the Nasdaq Capital Market.
After reviewing the company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, it was revealed that RedHill reported a stockholders' deficit amounting to $4,683,000. This deficit signifies that the company does not meet the alternative compliance options across market value of listed securities or net income from ongoing operations. Therefore, the notification does not affect the company's current listing status immediately, nor does it interfere with its ongoing business operations.
Actions to Regain Compliance
Although the initial notification does not alter RedHill's listing, it does require prompt action as the company has a period of 45 days to present a compliance plan. The deadline for submission is approaching, with the company needing to act quickly to ensure its continued presence on the Nasdaq Capital Market. Should Nasdaq accept this compliance plan, RedHill could receive an extension of up to 180 days to demonstrate compliance with the listing rule.
Assessing Options for Compliance
In light of this notification, RedHill is actively exploring various options to regain compliance. The company is committed to submitting its proposed plan to Nasdaq in a timely manner. However, there is no guarantee that the plan will be approved or whether the company can meet the necessary compliance requirements afterward.
About RedHill Biopharma
RedHill Biopharma Ltd. is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments targeting gastrointestinal diseases, oncology, and infectious diseases. One of its notable FDA-approved products is Talicia, a treatment designed for adults suffering from Helicobacter pylori (H. pylori) infections. The company is not only focused on markets in the U.S. but also plans to expand its marketing authorization into other territories.
Clinical Development Programs
RedHill has several late-stage clinical development programs in progress. These include:
- Opaganib (ABC294640): A first-in-class sphingosine kinase-2 (SPHK2) inhibitor that has shown promise in anticancer, anti-inflammatory, and antiviral activities. Its development targets indications associated with radiation and chemical exposure, particularly gastrointestinal acute radiation syndrome, as well as prostate cancer and COVID-19.
- RHB-204: A combination antibiotic therapy prepared for treating Crohn's disease and pulmonary nontuberculous mycobacterial disease.
- RHB-104: This has had a successful Phase 3 study focusing on Crohn's disease.
- RHB-107 (upamostat): An oral serine protease inhibitor currently in late-stage development for COVID-19 and other cancer treatments.
- RHB-102: Targeting chemotherapy-induced nausea and positive results from various clinical trials for gastrointestinal issues.
RedHill has partnerships with companies such as Hyloris Pharma, which aids in the global development of its products.
Company Contact Information
For inquiries, please reach out to:
Adi Frish
Chief Corporate and Business Development Officer
RedHill Biopharma
+972-54-6543-112
Frequently Asked Questions
1. What does the Nasdaq notification mean for RedHill Biopharma?
The notification indicates that RedHill is currently not in compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq.
2. What is RedHill Biopharma's plan to address the notification?
The company is exploring options and intends to submit a compliance plan to Nasdaq to regain its listing status.
3. What are the implications of a stockholders' deficit?
A stockholders' deficit means that the company's liabilities exceed its assets, impacting its compliance with Nasdaq requirements.
4. How long does RedHill Biopharma have to submit its compliance plan?
RedHill has 45 days from receiving the notification to submit its compliance plan to Nasdaq.
5. What are RedHill Biopharma's key products?
Some key products include Talicia, opaganib, RHB-204, RHB-104, and RHB-102, focusing on various medical conditions.
